These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 1444883)

  • 21. Positron emission tomography measures of benzodiazepine receptors in Huntington's disease.
    Holthoff VA; Koeppe RA; Frey KA; Penney JB; Markel DS; Kuhl DE; Young AB
    Ann Neurol; 1993 Jul; 34(1):76-81. PubMed ID: 8390806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuropsychological and neuroradiological correlates in Huntington's disease.
    Starkstein SE; Brandt J; Folstein S; Strauss M; Berthier ML; Pearlson GD; Wong D; McDonnell A; Folstein M
    J Neurol Neurosurg Psychiatry; 1988 Oct; 51(10):1259-63. PubMed ID: 2976080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurochemical correlates of caudate atrophy in Huntington's disease.
    Padowski JM; Weaver KE; Richards TL; Laurino MY; Samii A; Aylward EH; Conley KE
    Mov Disord; 2014 Mar; 29(3):327-35. PubMed ID: 24442623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional caudate imaging in symptomatic Huntington's disease: positron emission tomography versus single-photon emission computed tomography.
    Martin WR; Hoskinson M; Kremer B; Maguire C; McEwan A
    J Neuroimaging; 1995 Oct; 5(4):227-32. PubMed ID: 7579751
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain glucose utilization in childhood Huntington's disease studied with positron emission tomography (PET).
    De Volder A; Bol A; Michel C; Cogneau M; Evrard P; Lyon G; Goffinet AM
    Brain Dev; 1988; 10(1):47-50. PubMed ID: 2967038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease.
    Kuwert T; Lange HW; Boecker H; Titz H; Herzog H; Aulich A; Wang BC; Nayak U; Feinendegen LE
    J Neurol; 1993 Nov; 241(1):31-6. PubMed ID: 8138819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measurement of caudate nucleus area--a more accurate measurement for Huntington's disease?
    Wardlaw JM; Sellar RJ; Abernethy LJ
    Neuroradiology; 1991; 33(4):316-9. PubMed ID: 1833664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study.
    Feigin A; Leenders KL; Moeller JR; Missimer J; Kuenig G; Spetsieris P; Antonini A; Eidelberg D
    J Nucl Med; 2001 Nov; 42(11):1591-5. PubMed ID: 11696626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease.
    Harris GJ; Pearlson GD; Peyser CE; Aylward EH; Roberts J; Barta PE; Chase GA; Folstein SE
    Ann Neurol; 1992 Jan; 31(1):69-75. PubMed ID: 1531910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebral glucose consumption measured by PET in patients with and without psychiatric symptoms of Huntington's disease.
    Kuwert T; Lange HW; Langen KJ; Herzog H; Aulich A; Feinendegen LE
    Psychiatry Res; 1989 Sep; 29(3):361-2. PubMed ID: 2532753
    [No Abstract]   [Full Text] [Related]  

  • 31. CT brainstem abnormalities in the differential diagnosis of Huntington's disease.
    Masucci EF; Borts FT; Kurtzke JF
    Comput Med Imaging Graph; 1990; 14(3):205-12. PubMed ID: 2140710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging of cerebral blood flow markers in Huntington's disease using single photon emission computed tomography.
    Reid IC; Besson JA; Best PV; Sharp PF; Gemmell HG; Smith FW
    J Neurol Neurosurg Psychiatry; 1988 Oct; 51(10):1264-8. PubMed ID: 2976081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropathologic correlation of computerized tomography in Huntington's disease.
    Terrence CF; Rao G
    South Med J; 1980 Jun; 73(6):817-8. PubMed ID: 6446759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Magnetic resonance imaging in Huntington's disease.
    Sethi KD
    Mov Disord; 1991; 6(2):186. PubMed ID: 1829138
    [No Abstract]   [Full Text] [Related]  

  • 35. External evaluation of a deep learning-based approach for automated brain volumetry in patients with huntington's disease.
    Haase R; Lehnen NC; Schmeel FC; Deike K; Rüber T; Radbruch A; Paech D
    Sci Rep; 2024 Apr; 14(1):9243. PubMed ID: 38649395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regional specificity of brain atrophy in Huntington's disease.
    Halliday GM; McRitchie DA; Macdonald V; Double KL; Trent RJ; McCusker E
    Exp Neurol; 1998 Dec; 154(2):663-72. PubMed ID: 9878201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case of Huntington's chorea with unilateral ectopic gray matter.
    Nauta HJ; Platts ME
    Can J Neurol Sci; 1981 May; 8(2):181-4. PubMed ID: 6457681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cortical glucose metabolism in Huntington's disease.
    Martin WR; Clark C; Ammann W; Stoessl AJ; Shtybel W; Hayden MR
    Neurology; 1992 Jan; 42(1):223-9. PubMed ID: 1531155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Local synchronicity in dopamine-rich caudate nucleus influences Huntington's disease motor phenotype.
    Kasper J; Eickhoff SB; Caspers S; Peter J; Dogan I; Wolf RC; Reetz K; Dukart J; Orth M
    Brain; 2023 Aug; 146(8):3319-3330. PubMed ID: 36795496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons.
    Aylward EH; Brandt J; Codori AM; Mangus RS; Barta PE; Harris GJ
    Neurology; 1994 May; 44(5):823-8. PubMed ID: 8190282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.